Journal Article (Review Article)

DKFZ-2023-00338

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png CAR-T Cell Therapy and the Gut Microbiota.

Asokan, S. (First author)DKFZ* ; Cullin, N.DKFZ* ; Stein-Thoeringer, C. K. ; Elinav, E. (Last author)DKFZ*

2023
MDPI Basel

This record in other databases:  

Please use a persistent id in citations: doi:10.3390/cancers15030794

Abstract: Chimeric antigen receptor (CAR) - T cell cancer therapy has yielded promising results in treating hematologic malignancies in clinical studies, and a growing number of CAR-T regimens are approved for clinical usage. While the therapy is considered of great potential in expanding the cancer immunotherapy arsenal, more than half of patients receiving CAR-T infusions do not respond, while others develop significant adverse effects, collectively indicating a need for optimization of CAR-T treatment to the individual. The microbiota is increasingly suggested as a major modulator of immunotherapy responsiveness. Studying causal microbiota roles possibly contributing to CAR-T therapy efficacy, adverse effects reduction, and prediction of patient responsiveness constitutes an exciting area of active research. Herein, we discuss the latest developments implicating human microbiota involvement in CAR-T therapy, while highlighting challenges and promises in harnessing the microbiota as a predictor and modifier of CAR-T treatment towards optimized efficacy and minimization of treatment-related adverse effects.

Keyword(s): CAR-T ; cancer ; microbiome ; microbiota ; therapeutics

Note: #EA:F220#LA:F220# / #DKFZ-MOST-Ca210#

---

Contributing Institute(s):

1. Mikrobiom und Krebs (F220)

Research Program(s):

1. 316 - Infektionen, Entzündung und Krebs (POF4-316) (POF4-316)

Appears in the scientific report 2023

---

Database coverage:
; ; BIOSIS Previews ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Web of Science Core Collection

---